कंपनी का अवलोकन
Arcturus Therapeutics Holdings Inc. operates as a specialized developer of messenger RNA (mRNA) medicines, with a primary strategic focus on creating therapeutics for rare diseases affecting the liver and respiratory systems. The enterprise functions within the Healthcare sector, specifically targeting the Biotechnology industry, a domain characterized by high research and development intensity and reliance on proprietary intellectual property. As of the latest reporting period, the company maintains a market capitalization of $233.64M and employs a workforce of 106 individuals to execute its scientific and commercial objectives. The annual revenue generated over the trailing twelve months stands at $82.03M, which, when combined with the market cap, indicates a valuation significantly higher than current sales, a common characteristic in early-stage biotechnology firms where future pipeline potential is priced into the equity rather than current cash flows.
वित्तीय स्वास्थ्य
The company reported a revenue of $82.03M for the trailing twelve months, yet this revenue generated a net income of -$65,783,000 and an EBITDA of -$73,235,000, revealing a substantial gap between top-line sales and profitability that highlights the heavy cost structure inherent in drug discovery and clinical trial phases. Despite the negative net income, the company demonstrated positive financial flexibility with free cash flow of $9.18M, suggesting that operational efficiencies or asset sales have helped preserve cash reserves despite significant non-cash expenses or R&D burn. The company's margins reflect this challenging financial landscape, with a gross margin of -36.8%, an operating margin of -435.1%, and a profit margin of -80.2%, indicating that costs of goods sold and operating expenses currently exceed both gross and total revenue generation. On the liability side, the company holds cash totaling $230.91M against a debt load of $25.00M, resulting in a debt-to-equity ratio of 11.68 which suggests a highly leveraged capital structure relative to its equity base, though the cash position provides a buffer. This liquidity is further confirmed by a current ratio of 6.64, indicating that current assets are more than six times current liabilities, thereby signaling strong short-term liquidity and the ability to meet immediate obligations without distress. However, the return metrics show a return on equity of -28.9% and a return on assets of -15.5%, which reveal that management effectiveness in generating profit from shareholder capital and total assets is currently negative due to the lack of realized earnings.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a trailing P/E ratio of N/A due to losses and a forward P/E of -1.95, implying that the market expects earnings to remain negative or that the current earnings trajectory is insufficient to support a traditional multiple. The price-to-book ratio stands at 1.09, suggesting that the market values the company at a slight premium over its book value, likely reflecting the intrinsic worth of its intellectual property and mRNA technology platforms despite current losses. Alternative valuation measures such as a price-to-sales ratio of 2.85 and an EV/EBITDA of -0.38 indicate that the company is being valued primarily on its revenue generation potential rather than profitability, a standard approach for biotech firms in the development stage. The stock price has exhibited significant volatility, trading between a 52-week high of $24.17 and a 52-week low of $5.85, meaning the current valuation sits within a wide historical range that reflects speculative sentiment regarding the pipeline's success. Furthermore, the company possesses a beta of 2.44, which indicates that its stock price is substantially more volatile than the broader market, moving with an intensity that is more than double the average equity market fluctuations.
Growth & Income
The growth profile is defined by a revenue growth year-over-year of -68.4% and an earnings growth of N/A, indicating a contraction in sales which is often a temporary phase for biotechnology companies transitioning from research phases to clinical trials or commercialization. Since earnings growth is not applicable due to negative net income, the focus remains on the revenue contraction which implies that the company is likely scaling back operations or shifting resources toward more advanced development programs rather than expanding top-line sales. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings are theoretically available for reinvestment but are currently consumed by operational deficits and strategic investments in the STARR and LUNAR technology platforms. Consequently, the overall growth and income profile is one of capital preservation and strategic reinvestment, where the absence of income distribution is a direct result of the company's lifecycle stage and its necessity to fund expensive development activities to achieve future profitability.